Cerasorb reliable bone graft substitute for curettage of benign bone tumors

43 patients suffering from benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity using the ABGS Cerasorb and included in the final analysis. Clinical follow-up exams with X-rays in two planes were performed 6 weeks, 3 months, 6 months, and 1 year after surgery.

Key findings of the study were:

• The study cohort consisted of 21 male and 22 female patients.

• Patients’ mean age at surgery was 42 years (range 15–70 years).

• After a mean follow-up period of 14.6 months, radiological consolidation following curettage was observed in all patients.

• Total resorption was observed in 16.3% of patients; in the other 83.7%, resorption was partial.

• In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within 6 weeks after primary surgery.

“In conclusion, based on our short-term observation, the β-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption” the authors commented.

Level of Evidence III; retrospective cohort study. 

Further reading:

Artificial Bone Graft Substitutes for Curettage of Benign and Low Grade Malignant Bone Tumors: Clinical and Radiological Experience with Cerasorb

Ulrike Susanne Wittig, Jörg Friesenbichler et al

Indian Journal of Orthopaedics (2023) 57:1409–1414

https://doi.org/10.1007/s43465-023-00919-1